Clinical Trials Logo

NRAS Gene Mutation clinical trials

View clinical trials related to NRAS Gene Mutation.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05340621 Active, not recruiting - Melanoma Clinical Trials

NAUTILUS: OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

Start date: May 11, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The NAUTILUS study is a Phase 1b/2, multi-center, open-label study in which patients with activating mutations in the RAS pathway (Phase 1b) and patients with NRAS-mutated Melanoma (Phase 2) will be treated with a combination of oral OKI-179 combined with the MEK inhibitor binimetinib.